Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
STOCKHOLM, April 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the Company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 16/760,910 entitled "Use of NOX Inhibitors for Treatment of Cancer". This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.
The allowed claims cover a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1 inhibitor. The patent, when issued, will have an anticipated expiration date in 2038.
"This is a significant value enhancing event for the global setanaxib franchise and we are delighted that we are able to expand product protection for setanaxib in the important area of oncology," said CEO Renée Aguiar-Lucander.
Calliditas has corresponding applications in several additional territories around the world, including a pending patent application in Europe.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
The global RNAi therapeutics...
RSi, a privately held revenue cycle management service provider that exclusively services hospitals and healthcare systems, has been awarded five 2024 Top Workplace honors. The awards were recently announced by the HR employee engagement technology...
Michael Karlfeldt, ND, PhD, Nasha Winters, ND, FABNO, LAc, DiplOM, and 40+ Experts Gather to Share the Latest Breakthroughs in Cancer Treatment
Key Takeaways:
The Cancer Breakthroughs Summit 2.0 aims to transform fear into confidence by providing...
Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today presented final data from a diabetic foot ulcer (DFU) clinical trial showing that Omeza® OCMtm plus offloading of weight on the...
The "China Biological Reagents Market (Molecular Biology Reagents, Proteins and Cell Reagents): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
The China biological...
Illumina, Inc. today announced that its executives will be speaking at the following investor conference:
RBC 2024 Global Healthcare Conference on May 14, 2024Fireside chat at 5:30am Pacific Time (8:30am Eastern Time)The webcast can be accessed...